<span item_type="fundamental" item_id="4ec5a3b34834d2b85de4fca889a6eace" counter_id="ST/US/MPLNW" env="prod"></span><span item_type="announcement" item_id="513776918036086785" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 231.3 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -4.38.</p><p>EBIT: As of FY2025 Q1, the actual value is USD 112.35 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Q1 2025 Revenues: $231.3 million, a decrease of 1.4% compared to $234.5 million in Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $71.3 million for Q1 2025, compared to $539.7 million for Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li><li>Adjusted EBITDA: $142.1 million for Q1 2025, compared to $146.8 million for Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li><li>Operating Income: $9.7 million for Q1 2025, compared to an operating loss of $486.4 million for Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used by Operating Activities: - $30.1 million for Q1 2025, compared to net cash provided by operating activities of $49.7 million for Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li><li>Free Cash Flow: - $68.9 million for Q1 2025, compared to $19.2 million for Q1 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The Company processed approximately $42.9 billion in claim charges during Q1 2025, identifying potential medical cost savings of approximately $6.2 billion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/a991claritevpressrelease-m.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Claritev reaffirms its full-year 2025 guidance, expecting revenues to be between a 2% decrease to flat compared to FY 2024, with an Adjusted EBITDA Margin of 62.5% to 63.5%.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/ctev-20250508.htm"></span></li><li>Capital expenditures are projected to be between $155 million to $165 million, and Free Cash Flow is expected to be between - $65 million to - $75 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/ctev-20250508.htm"></span></li></ul>

CLARITEV CORPORATION C/WTS 08/10/2025(TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 231.3 M